Kingsview Wealth Management’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.2M | Sell |
134,751
-22,205
| -14% | -$2.56M | 0.22% | 84 |
|
|
2025
Q4 | $16.5M | Sell |
156,956
-60,214
| -28% | -$5.65M | 0.24% | 78 |
|
|
2025
Q3 | $18.2M | Buy |
217,170
+44,655
| +26% | +$3.68M | 0.28% | 63 |
|
|
2025
Q2 | $13.7M | Sell |
172,515
-30,938
| -15% | -$2.46M | 0.23% | 76 |
|
|
2025
Q1 | $18.3M | Buy |
203,453
+8,397
| +4% | +$784K | 0.34% | 50 |
|
|
2024
Q4 | $19.4M | Sell |
195,056
-150,169
| -43% | -$15.5M | 0.38% | 46 |
|
|
2024
Q3 | $39.2M | Buy |
345,225
+55,441
| +19% | +$6.59M | 0.82% | 23 |
|
|
2024
Q2 | $35.9M | Buy |
289,784
+23,241
| +9% | +$2.99M | 0.85% | 22 |
|
|
2024
Q1 | $35.2M | Buy |
266,543
+26,020
| +11% | +$3.21M | 0.88% | 19 |
|
|
2023
Q4 | $26.2M | Buy |
240,523
+156,563
| +186% | +$16.3M | 0.78% | 22 |
|
|
2023
Q3 | $8.64M | Buy |
83,960
+11,814
| +16% | +$1.27M | 0.31% | 74 |
|
|
2023
Q2 | $8.32M | Sell |
72,146
-7,137
| -9% | -$810K | 0.33% | 66 |
|
|
2023
Q1 | $8.43M | Sell |
79,283
-14,090
| -15% | -$1.52M | 0.35% | 59 |
|
|
2022
Q4 | $10.4M | Sell |
93,373
-2,949
| -3% | -$301K | 0.45% | 49 |
|
|
2022
Q3 | $8.29M | Buy |
96,322
+16,490
| +21% | +$1.47M | 0.39% | 59 |
|
|
2022
Q2 | $7.28M | Buy |
79,832
+17,833
| +29% | +$1.58M | 0.35% | 69 |
|
|
2022
Q1 | $5.09M | Buy |
61,999
+1,591
| +3% | +$125K | 0.22% | 106 |
|
|
2021
Q4 | $4.63M | Buy |
60,408
+970
| +2% | +$77.3K | 0.19% | 117 |
|
|
2021
Q3 | $4.46M | Buy |
59,438
+60
| +0.1% | +$4.56K | 0.21% | 110 |
|
|
2021
Q2 | $4.63M | Sell |
59,378
-258
| -0.4% | -$19.2K | 0.23% | 100 |
|
|
2021
Q1 | $4.39M | Buy |
59,636
+571
| +1% | +$42.1K | 0.25% | 92 |
|
|
2020
Q4 | $4.61M | Buy |
59,065
+1,971
| +3% | +$151K | 0.33% | 70 |
|
|
2020
Q3 | $4.52M | Buy |
57,094
+643
| +1% | +$50.4K | 0.4% | 61 |
|
|
2020
Q2 | $4.17M | Buy |
56,451
+26,996
| +92% | +$2.03M | 0.42% | 62 |
|
|
2020
Q1 | $2.16M | Buy |
29,455
+6,972
| +31% | +$548K | 0.29% | 94 |
|
|
2019
Q4 | $1.95M | Buy |
22,483
+5,249
| +30% | +$431K | 0.24% | 113 |
|
|
2019
Q3 | $1.38M | Buy |
17,234
+928
| +6% | +$74.4K | 0.22% | 133 |
|
|
2019
Q2 | $1.3M | Buy |
16,306
+953
| +6% | +$73K | 0.22% | 123 |
|
|
2019
Q1 | $1.22M | Sell |
15,353
-40,208
| -72% | -$3.01M | 0.19% | 145 |
|
|
2018
Q4 | $4.05M | Buy |
55,561
+711
| +1% | +$50.2K | 0.88% | 22 |
|
|
2018
Q3 | $3.71M | Buy |
54,850
+1,795
| +3% | +$114K | 0.75% | 30 |
|
|
2018
Q2 | $3.07M | Buy |
53,055
+739
| +1% | +$41.7K | 0.73% | 37 |
|
|
2018
Q1 | $2.72M | Buy |
52,316
+42,976
| +460% | +$2.32M | 0.68% | 42 |
|
|
2017
Q4 | $501K | Sell |
9,340
-872
| -9% | -$48.3K | 0.18% | 172 |
|
|
2017
Q3 | $624K | Buy |
10,212
+1,143
| +13% | +$69.3K | 0.27% | 116 |
|
|
2017
Q2 | $555K | Buy |
9,069
+1,114
| +14% | +$67.8K | 0.29% | 109 |
|
|
2017
Q1 | $482K | Buy |
+7,955
| New | +$483K | 0.29% | 120 |
|
Other funds holding MRK
VCM
VPM
Kingsview Wealth Management's MRK Position: Q1 2026 in Review
Kingsview Wealth Management reduced its Merck (MRK) stake by 14% in Q1 2026, selling an estimated $2.56M and leaving 134,751 shares worth $16.2M. The position accounts for 0.22% of the portfolio, ranked #84.
Kingsview Wealth Management first reported a position in MRK in Q1 2017 and has held it in 37 quarters since. The position peaked at $39.2M in Q3 2024. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Kingsview Wealth Management held 134,751 shares of Merck worth $16.2M as of Q1 2026.
- Kingsview Wealth Management sold 22,205 Merck shares in Q1 2026, an estimated $2.56M.
- Merck made up 0.22% of Kingsview Wealth Management's portfolio in Q1 2026, its #84 holding.
- Kingsview Wealth Management first reported a position in Merck in Q1 2017 and has held it in 37 quarters since.
- Kingsview Wealth Management's Merck position peaked at $39.2M in Q3 2024.
- 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Kingsview Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.